TargetBeta
PTGS1
prostaglandin-endoperoxide synthase 1 · also COX1, PGHS-1, PTGHS · Prostaglandin-endoperoxide synthase family
10 programs in company-led studies act on PTGS1, from 10 companies: 1 in phase 3, 9 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Aspirinrule | Bayer | phase 4 | 844 running | PTGS2 | ChEMBL |
| Acetaminophenrule | Johnson & Johnson | phase 4 | 1363 running | FAAH, PTGS2, TRPV1 | ChEMBL |
| Ibuprofenrule | Pfizer | phase 4 | 1132 running | PTGS2 | ChEMBL |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 71 running | ALOX5, PTGS2 | ChEMBL |
| dexibuprofenrule | Aponia Laboratories | phase 4 | 61 running | PTGS2 | ChEMBL |
| Benzydaminerule | Angelini Pharma | phase 4 | 41 running | PTGS2 | ChEMBL |
| Dipyronerule | Hypera Pharma | phase 4 | 41 running | PTGS2 | ChEMBL |
| dexketoprofenrule | Menarini Group | phase 4 | 80 running | PTGS2 | ChEMBL |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 40 running | PTGS2 | ChEMBL |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 120 running | PTGS2 | ChEMBL |
Conditions their studies are in
- Pain, 4 programs
- Fever, 3 programs
- Acute Pain, 2 programs
- Common Cold, 2 programs
- Dysmenorrhea, 2 programs
- Migraine Disorders, 2 programs
- Pain, Postoperative, 2 programs
- Anemia, 1 program
- Ankle Injuries, 1 program
- Arthritis, Juvenile, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Sulfasalazine · Bristol-Myers Squibb · phase 4 · NCT07726368
- Jan 27, 2027Acetaminophen · Johnson & Johnson · phase 4 · NCT07508241
- Jan 31, 2027Aspirin · Bayer · phase 4 · NCT07853248
- Mar 2027Ibuprofen · Pfizer · phase 4 · NCT07225634
- Jun 2027dexibuprofen · Aponia Laboratories · phase 4 · NCT07930559
- Jun 28, 2027Dipyrone · Hypera Pharma · phase 4 · NCT07626437
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.